Analysts forecast that Repligen Co. (NASDAQ:RGEN) will post $0.18 earnings per share for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Repligen’s earnings, with estimates ranging from $0.17 to $0.20. Repligen posted earnings per share of $0.21 during the same quarter last year, which suggests a negative year-over-year growth rate of 14.3%. The business is expected to report its next earnings results on Thursday, February 20th.
On average, analysts expect that Repligen will report full year earnings of $1.03 per share for the current financial year, with EPS estimates ranging from $1.02 to $1.04. For the next year, analysts anticipate that the business will post earnings of $1.11 per share, with EPS estimates ranging from $0.97 to $1.22. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Repligen.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, October 31st. The biotechnology company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.07. The business had revenue of $69.45 million for the quarter, compared to the consensus estimate of $66.10 million. Repligen had a return on equity of 6.50% and a net margin of 9.28%. The company’s quarterly revenue was up 40.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 EPS.
Several institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. grew its position in shares of Repligen by 53.0% during the 2nd quarter. Invesco Ltd. now owns 3,088,594 shares of the biotechnology company’s stock worth $265,465,000 after buying an additional 1,069,284 shares during the period. BlackRock Inc. boosted its holdings in shares of Repligen by 12.4% in the 2nd quarter. BlackRock Inc. now owns 6,350,552 shares of the biotechnology company’s stock worth $545,830,000 after purchasing an additional 699,886 shares during the period. State Street Corp boosted its holdings in shares of Repligen by 27.9% in the 3rd quarter. State Street Corp now owns 2,348,254 shares of the biotechnology company’s stock worth $180,088,000 after purchasing an additional 512,455 shares during the period. Nuveen Asset Management LLC boosted its holdings in shares of Repligen by 1,207.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 362,408 shares of the biotechnology company’s stock worth $31,149,000 after purchasing an additional 334,696 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Repligen by 7.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,420,485 shares of the biotechnology company’s stock worth $379,940,000 after purchasing an additional 305,195 shares during the period. Hedge funds and other institutional investors own 85.46% of the company’s stock.
Repligen stock opened at $99.02 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 14.70 and a current ratio of 16.03. The business’s 50-day simple moving average is $91.60 and its two-hundred day simple moving average is $86.59. The company has a market cap of $5.15 billion, a PE ratio of 135.64, a PEG ratio of 4.47 and a beta of 1.12. Repligen has a fifty-two week low of $52.87 and a fifty-two week high of $99.49.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Read More: Are sell-side analysts objective?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.